Loading market dashboard
IDEXX Laboratories, Inc.
IDXXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
IDEXX Laboratories NASDAQ: IDXX President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company's innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics.
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 27, 2026 from 10:55 am – 11:25 am (ET). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will b.
On May 11, 2026, IDEXX Laboratories Inc (IDXX) shares fell 5.0% to a current price of $532.00. This decline comes amid a challenging performance period for the
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
IDXX rides strong on Q1 beats with rising margins; lifts 2026 outlook as diagnostics growth and innovation momentum fuel performance.
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories Inc (NASDAQ:IDXX) shares are up on Tuesday as the company recently announced strong first-quarter results, showcasing a 14% revenue growth.
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.96 per share a year ago.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter earnings per diluted share (“EPS”) were $3.47, an increase of 17% as reported and 15% on a c.
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
IDXX heads into Q1 earnings with strong growth forecasts, steady estimate beats, and momentum in diagnostics and recurring revenue streams.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Comerica Bank lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 35.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,493 shares of the company's stock after selling 9,639 shares during the quarter. Comerica Bank's holdings in IDEXX Laboratories
On April 29, 2026, we take a closer look at the DCF analysis for IDEXX Laboratories Inc (IDXX). The company has experienced a price performance of -0.1% over th
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYK heads into Q1 earnings with strong procedure demand and robotic surgery growth, but tariff and cost pressures may test margins.
A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Maine's research and workforce landscape across sectors. A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Maine's research and workforce landscape across sectors.
AEGON ASSET MANAGEMENT UK Plc reduced its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 4.6% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,068 shares of the company's stock after selling 1,247 shares during the quarter. AEGON ASSET MANAGEMENT UK
On April 23, 2026, we delve into the DCF analysis for IDEXX Laboratories Inc (IDXX), a company currently priced at $578.35. Over the past year, IDXX has demonst
Idexx Laboratories, Inc. and Zoetis Inc. are dominant players in animal health, but IDXX outperforms due to superior capital efficiency and recurring revenue flywheel. ZTS trades at a much lower valuation with solid margins and a dependable pipeline, but requires catalysts—like EPS beats or new approvals—for rerating in 2026. IDXX commands a premium valuation, driven by high ROIC (37–49%) and robust growth in diagnostics, notably its Cancer DX test and InVue DX instrument adoption.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Assetmark Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,769 shares of the company's stock after acquiring an additional 1,518 shares during the period.
IDEXX Laboratories, Inc. IDXX is expanding its global commercial capabilities to support continued growth in its CAG Diagnostics recurring revenue stream. The company's software ecosystem remains a key pillar of its value proposition.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDXX stock surges over the past year, fueled by strong diagnostics growth, innovation traction and expanding global demand in pet healthcare markets.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2026 Earnings Snapshot through a link on the IDEXX website,.
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
Beacon Investment Advisory Services Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 11.9% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 62,951 shares of the company's stock after buying an additional 6,710 shares during the period. IDEXX Laboratories accounts for
Congress Asset Management Co. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 9,894.0% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,908 shares of the company's stock after purchasing an additional 152,368 shares during the quarter. Congress
Procyon Advisors LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,905 shares of the company's stock, valued at approximately $1,966,000. A number of other hedge funds have also recently
Achmea Investment Management B.V. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 319.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,769 shares of the company's stock after acquiring an additional 13,537 shares during the quarter.
Banco Bilbao Vizcaya Argentaria S.A. lifted its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 342.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,140 shares of the company's stock after purchasing an additional 10,943 shares during the quarter. Banco Bilbao Vizcaya
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.
Investors with an interest in Medical - Instruments stocks have likely encountered both SONOVA HOLDING (SONVY) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Nimrata Hunt sold 1,758 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares
Barclays PLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 22.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,670 shares of the company's stock after selling 68,510 shares during the quarter. Barclays PLC owned
B. Metzler seel. Sohn and Co. AG trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 20.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,947 shares of the company's stock after selling 4,388 shares during the quarter. B. Metzler seel.
